cancers Article Targeting BRF2 in Cancer Using Repurposed Drugs Behnam Rashidieh 1,* , Maryam Molakarimi 2, Ammar Mohseni 2, Simon Manuel Tria 1,3, Hein Truong 1, Sriganesh Srihari 1, Rachael C. Adams 1 , Mathew Jones 4, Pascal H. G. Duijf 5,6, Murugan Kalimutho 1 and Kum Kum Khanna 1,* 1 QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia;
[email protected] (S.M.T.);
[email protected] (H.T.);
[email protected] (S.S.);
[email protected] (R.C.A.);
[email protected] (M.K.) 2 Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University (TMU), Nasr Bridge, Tehran 14115-154, Iran;
[email protected] (M.M.);
[email protected] (A.M.) 3 School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia 4 The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4102, Australia;
[email protected] 5 Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia;
[email protected] 6 Centre for Data Science, Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia * Correspondence:
[email protected] (B.R.);
[email protected] (K.K.K.) Simple Summary: BRF2, a subunit of the RNA polymerase III transcription complex, is upregulated in a wide variety of cancers and is a potential therapeutic target; however, no effective drugs are available to target BRF2. The upregulation of BRF2 in cancer cells confers survival via the prevention Citation: Rashidieh, B.; of oxidative stress-induced apoptosis.